5th Apr 2016 09:46
LONDON (Alliance News) - Sareum Holdings PLC said Tuesday the UK Medicines and Healthcare Products Regulatory Agency has approved clinical trial applications for its CCT245737 drug candidate in cancer patients.
The company expects to begin the clinical trials in the second quarter of 2016, although these are still subject to final approval from the National Health Service.
Two trials are planned in collaboration with co-development partners, one using CCT245737 in combination with standard-of-care chemotherapy, targeting lung and pancreatic cancer patients, whilst the other will use CCT245737 as a single anti-cancer agent, targeting various cancers.
"This approval for CCT245737 is another significant milestone along its path to being the first from our development pipeline to enter clinical trials," said Chief Executive Officer Tim Mitchell in a statement.
Shares in Sareum were up 9.1% at 0.780 pence Tuesday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Sareum